Abbisko and AstraZeneca Join Forces on Lung Cancer Drug Combo
Abbisko and AstraZeneca are teaming up to develop a lung cancer drug combination following trial clearance in China.
Two pharmaceutical heavyweights are joining forces to take on one of the world's deadliest diseases. Abbisko Therapeutics and AstraZeneca have announced a collaboration to develop a combination therapy targeting lung cancer, a move that comes on the heels of receiving clinical trial clearance in China. For patients and investors alike, this kind of partnership signals that both companies see serious potential in pairing their respective drug candidates.
Collaboration deals like this one are pretty common in pharma — and for good reason. Developing a single cancer drug costs billions of dollars and takes years of testing. By teaming up, two companies can split the risk, share resources, and potentially fast-track a treatment that neither could bring to market as quickly on their own. In this case, AstraZeneca brings its deep oncology expertise to the table, while Abbisko contributes its pipeline and regional footing in China.
Read more Clarivate Launches AI Platform to Streamline IP Workflows →
The China trial clearance piece is worth paying attention to. China has one of the highest rates of lung cancer globally, driven in part by air pollution and high smoking rates, making it a critical market for any new treatment in this space. Getting the green light to run clinical trials there opens the door to a massive patient population and, if results are promising, a huge commercial opportunity down the line.
For everyday investors or anyone following the oncology space, this deal is a reminder that the race to crack lung cancer treatment is nowhere near over. Combination therapies — where two drugs work together to attack cancer from different angles — have become a major focus of research because cancer cells can become resistant to a single treatment over time. Whether this particular pairing proves effective will depend on what the trial data eventually shows.
Continue reading at Yahoo Finance.
